Integrating Biosimilars Into Retina and Neurology Practices Requires Careful Planning
Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.
Related Articles
New FTC Report Finds PBMs Increased Prices for Specialty Cancer, HIV Generic Drugs to Generate Billions in Revenue
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for…
FDA Grants Additional Fast Track Designation to Emiltatug Ledadotin to Treat HER2 Low, HER2-Negative Breast Cancer
A new indication for the antibody-drug conjugate expands the future clinical potential of the treatment in patients with the rare breast cancer.
Use of radiofrequency ablation of the vaginal canal for genitourinary syndrome of menopause
AbstractBackground. Genitourinary syndrome of menopause (GSM) is a prevalent condition with a constellation of symptoms including burning, dryness, dyspare
ACP Hospitalist
ACP Hospitalist provides hospital-based physicians with news and information about the practice of hospital medicine.
See the Harm | NEJM
Medical students are faced with a dilemma: for them to learn, enough people have to get sick, with varied and sometimes terrible illnesses. In order…
Balancing precision and affordability in assessing infant development in large-scale mortality trials: secondary analysis of a randomised controlled trial
Objective Large-scale mortality trials require reliable secondary assessments of impairment. We compared the Ages and Stages Questionnaire (ASQ-3), a screening tool self-administered by parents, in…
Patient Complexity and Hospitalization Outcomes at Academic and Community Hospitals
This cohort study compares differences in patient case mix and clinical outcomes between academic and community hospitals among patients admitted to general medicine in Ontario,…
FDA Bans Red No. 3 Artificial Dye in Food, Ingested Drugs
The FDA cites cancer risk and the Delany Clause in its decision to revoke food and drug uses of the dye.
Brentuximab Vedotin Induces Cell Death, Protects Healthy Cells in Breast Cancer Treatment
Brentuximab vedotin is approved for treatment of adult and pediatric with classical Hodgkin lymphoma in combination with chemotherapy.
